A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients.
about
Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapySafety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort studyCare of the HIV-infected pregnant woman in the developed worldPrevention of mother-to-child transmission in South Africa: an ever-changing landscapeAdverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medicationPlasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole.A sensitive and specific liquid chromatography/tandem mass spectrometry method for quantification of nevirapine and its five metabolites and their pharmacokinetics in baboonsNevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South AfricaHepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon.Design of the anti-tuberculosis drugs induced adverse reactions in China National Tuberculosis Prevention and Control Scheme Study (ADACS).Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire.Extensive pulmonary involvement with raltegravir-induced DRESS syndrome in a postpartum woman with HIV.Laboratory adverse events and discontinuation of therapy according to CD4(+) cell count at the start of antiretroviral therapyAdverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria.Persistent high nevirapine blood level with DRESS syndrome 12 days after interruption of antiretroviral therapyEvaluating the utility of early laboratory monitoring of antiretroviral-induced haematological and hepatic toxicity in HIV-infected persons in Cameroon.Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.Hypersensitivity reactions to HIV therapy.Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects.The Expanding Class of Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV-1 InfectionEffect of anemia on hepatotoxicity of HAART in HIV patients in Benin cityDrug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors.Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 > or = 50 cells/mm3.A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy.Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity.Nevirapine in the treatment of HIV.Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretroviralsThe role of the immune system in nevirapine-induced subclinical liver injury of a rat model.Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back again.Combining Non-randomized and Randomized Data in Clinical Trials Using Commensurate PriorsTreatment of hepatitis C in HIV-coinfected patients.Pharmacological and clinical evidence of nevirapine immediate- and extended-release formulationsThe clinical implications of antiretroviral pharmacogenomics.Association of Nevirapine Levels with Rash or Hepatotoxicity Among HIV-Infected Thai Women.Management of advanced HIV disease in patients with tuberculosis or hepatitis co-infection.Underreporting of side effects of standard first-line ART in the routine setting in Blantyre, MalawiLiver toxicity induced by non-nucleoside reverse transcriptase inhibitors.Adverse effects of highly active antiretroviral therapy in developing countries.High treatment success rates when switching to once daily nevirapine containing antiretroviral therapy
P2860
Q24245940-622BAC67-DCAA-4DEA-BC64-2F2DF3D09876Q24811445-49A45D03-0611-42D5-96FC-889FB6EAFF6FQ28082774-213B307B-B1F6-4E2E-970C-D14870592882Q28083088-94E45A34-E2FF-4AF1-BF00-1559AB92DB63Q28749406-CDE1F2BF-52F5-49EA-B0E6-3A48C5107F1DQ33277939-C73DC99D-D53F-4948-8D7A-62E3E3A08038Q33514519-BF6E41A6-B251-4662-AF76-7AF29B993C9CQ33533366-26F12B0B-4B2B-4D99-A3B7-6428FFC68DBBQ33535469-3D9BCA3B-F629-4BDA-95A8-C264CF4A49DCQ33584259-6C995156-27EE-4B7F-B7BC-AF3A2C9400A9Q33615251-A8016EC7-74EE-4144-8312-4A977DE0892AQ33628702-CF4D9E07-1ADF-4ED8-BFD8-A73D8E6BA1AAQ33654668-A3951C3F-CABF-4502-A402-5DA787DB4D76Q34174009-0310F5B0-EF66-47E4-846D-1A2EEBCA591BQ34522575-30865E12-58CE-4991-973E-C2971990E44BQ34670487-EE76AFB4-64B6-4821-9797-739B88B51D4FQ34975110-5C5DBABD-8E2C-4FDD-8E2E-3A5745EE3DE4Q34976463-D6652760-AE94-4DDA-A983-534CA6064A8FQ35023348-AAD1CD06-77F0-4E80-A3C5-9827DA76A2C1Q35111300-80AD351E-58ED-4C19-90AE-FE559F3BC5F6Q35542957-91029309-AC0E-4B60-8FC7-42EEA0201F11Q35676417-20A83E58-3484-47B6-8920-AE9FF065B024Q35689833-18263AAA-141D-4238-B892-FE4161687660Q35827891-FC6BB394-F6D2-4DF0-8290-33BC56721B68Q35873680-42E4CE1C-DFA4-4331-B5C3-1BD0A671953CQ35917412-B256C62B-F1E0-45AB-839E-04873FAA9074Q36073787-FE41DB2F-DDB4-4A32-A684-7ACCFFA67EE7Q36200176-F88AC66D-5330-4288-BB78-7A3101F4FEFFQ36286145-0E1C9652-EFC0-4932-8A39-4451B8136B4AQ36341730-981F1BD2-08DE-44C4-BC3E-6CA49453A8AAQ36359341-CAED4A0B-C140-4FBF-A377-C4BE77237C8CQ36409500-219718DF-33C6-4037-BB52-51A4E6BF33A8Q36410952-4C9E4CA1-68F9-4C05-8015-4693AA36BAC4Q36497078-BF64FB01-A119-4C35-A38E-3021862E623EQ36508979-0DBB6CB6-7DC1-40F0-B0A9-A95DE23F5F0EQ36558753-F11B02EE-3DAF-401D-B64C-6C8CAC5F090FQ36657527-0E8CD310-1884-47DC-87B1-933AA5476904Q36718901-425D627D-F1E9-45A1-ACC6-6FBFDFD3DDB5Q36945761-7C6E98AB-D1CB-4DD2-8E89-9F56F165FF9CQ37063896-D71C89CE-E655-449A-A0CB-A21F722CB05A
P2860
A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
A comprehensive hepatic safety ...... ions of HIV infected patients.
@en
A comprehensive hepatic safety ...... ions of HIV infected patients.
@nl
type
label
A comprehensive hepatic safety ...... ions of HIV infected patients.
@en
A comprehensive hepatic safety ...... ions of HIV infected patients.
@nl
prefLabel
A comprehensive hepatic safety ...... ions of HIV infected patients.
@en
A comprehensive hepatic safety ...... ions of HIV infected patients.
@nl
P2093
P1476
A comprehensive hepatic safety ...... ions of HIV infected patients.
@en
P2093
Douglas L Mayers
James Love
Jerry O Stern
Michael S Imperiale
Patrick A Robinson
Stephan Lanes
P304
P356
10.1097/00126334-200309011-00005
P407
P478
34 Suppl 1
P577
2003-09-01T00:00:00Z